secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K/A
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001213900-24-017544
Event type: m_and_a
Sentiment:  negative
Materiality: 0.80
Item codes: 2.01, 9.01, 8.01, 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconetix completes Proteomedix acquisition; target shows $27.2M deficit, going concern
--------------------------------------------------------------------------------

- Proteomedix 2022 revenue $392K, net loss $2.04M; accumulated deficit $27.2M as of Dec 31, 2022.
- Total liabilities $6.86M vs stockholders' deficit $5.79M; cash only $470K at year-end 2022.
- Auditor's report includes substantial doubt about Proteomedix's ability to continue as going concern.
- Onconetix issued stock for 100% of Proteomedix equity on Dec 15, 2023; acquisition previously disclosed.
- Pro forma financials and unaudited interim statements through Sep 30, 2023 now filed with SEC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390024017544/0001213900-24-017544-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390024017544/ea0200807-8ka2_onconetix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-017544

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer